ASEP Medical ($ASEP.c) up 15% in the wake of announcing that its novel antibiofilm peptide technology is in advanced development with pre-clinical partner iFyber, and grant funding from the US Army Medical Research and Materiel Command!
iFyber is a preclinical contract research organization with antimicrobial wound dressings, biomaterials, and wound care management.
$ASEP's partnership with iFyber is focused on developing wound dressings that incorporate ASEP's novel peptide technology into advanced and effective wound dressings to prevent and treat biofilm-associated wounds as well as burns and soft tissue infections. Additionally, the dressings are expected to promote wound healing which is essential when treating injuries in the field.
$ASEP holds an exclusive global license to a patented technology developed by world-leading microbiologist Dr. Robert E.W. Hancock and his team at UBC.
This is a significant milestone for $ASEP as there is not a single FDA-approved treatment for biofilm infections although biofilm infections represent 65% of all infections, providing a great opportunity for $ASEP as they are addressing the medical shortcoming directly.
https://www.newswire.ca/news-releases/asep-medical-inc-announces-its-antibiofilm-anti-inflammatory-peptide-technology-is-in-advanced-development-for-wound-dressings-with-us-army-funding1-828732764.html